Trial · NCT02756663
Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
NCT02756663, Phase 2, Withdrawn, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma. Trials, record NCT02756663. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02756663
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
- NCT number
- NCT02756663
- Status
- Withdrawn
- Phases
- Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Multiple Myeloma
- Interventions
- panobinostat (capsules), carfilzomib (infusion), dexamethasone (tablets)
- First posted
- 2016-04-29
- Last updated
- 2016-11-08
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) using investigator's response assessment | All patients treated for 6 cycles (cycle=28 days) | The primary endpoint if Overall Response Rate (ORR) using investigator response assessment according to IMWG criteria. The analysis of ORR will be performed after all randomized patients have completed 6 months of study treatment or discontinued treatment earlier. |
| Secondary | Very Good Partial Response (VGPR) or better as best response using investigator response assessment based on International Myeloma Working Group (IMWG) criteria | All patients treated for 6 cycles (cycle=28 days) | Investigators' response assessment assessed on IMWG criteria will be used. The VGPR or better rate is defined as the proportion of patients with a confirmed VGPR or better response as their best overall response. |
| Secondary | Progression-free survival (PFS) using investigator's response assessment based on IMWG criteria | All patients treated for 6 cycles (cycle=28 days) | PFS is defined as the time from date of randomization to date of first documented disease progression or death (regardless of cause of death). |
| Secondary | Overall survival (OS) | All patients treated for 6 cycles (cycle=28 days) | OS is defined as the time from date of randomization to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. |
| Secondary | Time to response (TTR) using investigator's response assessment based on IMWG criteria | All patients treated for 6 cycles (cycle=28 days) | TTR is the time between date of randomization to the date of first onset of partial response (PR) or better response. |
| Secondary | Duration of Response (DOR) using investigator's response assessment based on IMWG criteria | All patients treated for 6 cycles (cycle = 28 days) | DOR is defined as the duration from the first documented onset of PR or better response the date of first documented disease progression or death due to multiple myeloma. DOR will use only the patients with PR or better as their best response. |
| Secondary | Time to progression (TTP) using investigator's response assessment based on IMWG criteria | All patients treated for 6 cycles (cycle = 28 days) | TTP is defined as the time from the date of randomization to the ate of the first documented disease progression or death due to multiple myeloma. |
| Secondary | Time to reach Cmax for panobinostat (PAN) and carfilzomib (CFZ) | All patients treated for 6 cycles (cycle=28 days); | The maximum (peak) observed plasma concentration after single and multiple dose administration (ng/mL) of PAN and CFZ. |
| Secondary | Minimum observed plasma concentration (Cmin) for carfilzomib | All patients treated for 6 cycles (cycle=28 days) | The minimum (trough) observed plasma concentration after single and multiple dose administration (ng/mL) of PAN and CFZ. |
| Secondary | Concentration of panobinostat in blood plasma in 48 hrs after the dose. | All patients treated for 6 cycles (cycle = 28 days) | The area under the concentration-time curve (AUC) from time zero to 48 hours (ng\*h/mL) after the dose of PAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02756663
GET https://conductscience.org/api/trials/v1/NCT02756663/registered